Prognostic impact of CD30 expression in de novo DLBCL. (A-B) OS (A) and PFS (B) of patients with CD30⁺ vs CD30^– DLBCL in the training set. (C) OS of patients with CD30⁺ vs CD30^– DLBCL in the validation set. These patients were part of an independent cohort of 442 patients with available survival information (supplementary Table 1). (D) OS of patients with CD30⁺ vs CD30^– DLBCL in combined training and validation sets.